Global Skin Cancer Diagnostics and Therapeutics Market Revenue Grows at a CAGR of 5.44%

Introduction

Straits Research released its highly anticipated report, “Global Skin Cancer Diagnostics and Therapeutics Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 14.62 billion in 2025 and is projected to expand to USD 23.50 billion by 2034, registering a compound annual growth rate (CAGR) of 5.44%.

Market Dynamics

The global skin cancer diagnostics and therapeutics market is witnessing substantial growth, driven by the rising incidence of skin cancers worldwide. Increasing exposure to ultraviolet radiation, coupled with lifestyle changes and a growing elderly population, led to a surge in both melanoma and non-melanoma cases, creating a strong demand for effective diagnostic and therapeutic solutions. Early detection technologies, including advanced imaging systems and molecular assays, are improving diagnostic accuracy, enabling timely intervention and better treatment outcomes.

On the contrary, the market faces challenges related to the high cost of advanced diagnostics and therapies. Sophisticated devices, genomic tests, and biologic treatments are expensive, limiting their accessibility in low and middle-income countries. The affordability barrier hampers the widespread adoption of innovative treatments and slows penetration in emerging markets, creating a restraint on overall market growth.

Despite these challenges, notable opportunities exist in expanding healthcare infrastructure and increasing awareness of skin health in emerging economies. As more patients seek early diagnosis and advanced treatment options, markets in Asia Pacific, Latin America, and in Middle East are expected to experience rapid growth. The combination of rising disease prevalence, technological advancements, and increasing accessibility positions the skin cancer diagnostics and therapeutics market for sustained expansion.

Market Highlights

• Type: The therapeutics segment dominated the market in 2025. This growth is attributed to the increasing number of people undergoing skin cancer treatment.
• Cancer Type: The melanoma segment is estimated to grow at the fastest pace with a CAGR of 6.74% in 2026-2034.
• Regional Insights: North America dominated the global market, accounting for 39.78% share in 2025, owing to high awareness of skin cancer prevention.

Competitive Players

1. Abbott
2. Amgen Inc.
3. AstraZeneca
4. Bayer AG
5. bioMérieux Inc.
6. Bristol Myers Squibb Company
7. Castle Biosciences Inc.
8. DermaSensor, Inc.
9. DermTech
10. Hoffmann‑La Roche Ltd.
11. GSK plc
12. Illumina, Inc.
13. Lilly
14. Merck & Co., Inc.
15. Novartis AG
16. Pfizer Inc.
17. QIAGEN
18. Quest Diagnostics Incorporated
19. Sanofi
20. Sun Pharmaceutical Industries Ltd.
21. Thermo Fisher Scientific Inc.
22. Others

Recent Developments

October 2025: DermaSensor Inc. raised USD 16 million Series B funding to fuel the commercial expansion of its FDA-cleared, non-invasive skin cancer detection solution.

Segmentation

1. By Type (2026-2034)
   1. Diagnostics
   2. Dermatoscopy
   3. Biopsy
   4. Genetic Tests
   5. Others
   6. Therapeutics
   7. Chemotherapy
   8. Immunotherapy
   9. Targeted Therapy
   10. Radiotherapy
   11. Others
2. By Cancer Type (2026-2034)
   1. Melanoma
   2. Non-melanoma